The protein kinase Syk is a key mediator of proximal B-cell receptor (BCR) signaling. Following antigen stimulation, Syk is recruited to the BCR and becomes activated by phosphorylation at Y352. Recently, Syk was found to be constitutively phosphorylated in several common B-cell lymphoma subtypes, indicating a role for antigen-independent Syk activation in the pathogenesis of these diseases. We now report that Syk is constitutively phosphorylated on the activating Y352 residue in chronic lymphocytic leukemia (CLL) B cells. To examine the effects of constitutive Syk activity on intracellular signaling and leukemic cell survival, we performed in vitro studies with the Syk inhibitor R406. Treatment with R406 induced leukemic cell apoptosis in the majority of investigated cases and affected the basal activity or expression of several pro-survival molecules regulated by Syk, including the Akt and extracellular signalregulated (ERK) kinases, and the anti-apoptotic protein Mcl-1. In addition, R406 prevented the increase in leukemic cell viability induced by sustained BCR engagement and inhibited BCR-induced Akt activation and Mcl-1 upregulation. Collectively, these data identify Syk as a potential target for CLL treatment and suggest that inhibition of this kinase could provide a double therapeutic benefit by disrupting both antigen-dependent and antigen-independent signaling pathways that regulate leukemic cell survival.
Introduction
Recent studies have provided substantial evidence that antigen selection plays an important role in the pathogenesis of chronic lymphocytic leukemia (CLL). [1] [2] [3] In particular, the expression of similar or virtually identical B-cell receptor (BCR) molecules by CLL B cells from different patients strongly suggests that antigen selection was involved in the initial development and expansion of the malignant clones. [4] [5] [6] Antigen stimulation is also considered important for subsequent disease progression, based on the strong association between the course of the disease and certain structural and functional features of the BCR. The latter include the mutational status of the immunoglobulin variable region genes and expression of the protein tyrosine kinase ZAP-70, both of which have been associated with a greater capacity of CLL B cells to signal through the BCR. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Additional evidence for a role of antigen stimulation in disease progression has been provided by gene expression and immunophenotyping studies, which have shown greater expression of BCR-regulated genes in cases with adverse prognostic features. 9, 17 Altogether, these data suggest that BCR-derived signals contribute to the pathogenesis of CLL at various stages of the disease, including the initial clonal expansion and during subsequent disease progression.
BCR signaling is a complex process that involves a number of kinases, phosphatases and adaptor proteins that transmit, modulate or terminate the signal. 18 The Syk protein tyrosine kinase is one of the key signaling molecules in this process. Following antigen stimulation, Syk is recruited to the tyrosinephosphorylated immunoreceptor tyrosine-based activation motifs in the Ig-a and Ig-b chain of the BCR and becomes activated by sequential phosphorylation at conserved tyrosine residues. The first event involves phosphorylation at Y352 by Lyn or other Src-family kinases, which results in the release of the kinase domain from an autoinhibitory configuration. Phosphorylation at Y352 is considered sufficient to increase Syk activity enough to phosphorylate certain downstream substrates and trans-autophosphorylate tyrosines 525 and 526 in the activation loop. [19] [20] [21] [22] [23] The function of the tyrosines in the activation loop has still not been completely resolved, but most studies indicate that their phosphorylation is required to fully convert or stabilize Syk in an active conformation. 22, 23 Once activated, Syk propagates the BCR signal by associating with adaptor proteins and phosphorylating important signaling intermediates, including B-cell linker protein (BLNK), PI3K (phosphatidylinositol 3-kinase) and PLCg2 (phospholipase Cg2). The signaling cascade then proceeds with the activation of downstream signaling molecules that regulate the cellular response, such as the Akt, extracellular signal-regulated kinase (ERK), c-JUN NH 2 -terminal kinase and the nuclear factor (NF)-kB transcription factor. 24 In CLL cells, BCR stimulation usually induces an incomplete signaling response, characterized primarily by the activation of the Akt and ERK kinases. 25 However, activation of Akt is sufficient to increase CLL-cell survival, provided that the BCR signal is of adequate duration. Thus, sustained activation of Akt, which can be induced by stimulation with immobilized anti-IgM antibodies, results in increased apoptosis resistance and upregulation of several antiapoptotic proteins, among which Mcl-1 appears primarily responsible for the increased leukemic cell survival. 25, 26 The Syk kinase has recently attracted additional attention following observations that it is constitutively activated in several common B-cell malignancies. Thus, antigen-independent phosphorylation of Syk at Y352 or Y525/526 has been observed in follicular lymphoma, diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. [27] [28] [29] [30] Inhibition or downregulation of Syk in DLBCL and follicular lymphoma cell lines resulted in decreased phosphorylation of downstream signaling molecules and inhibition of proliferation and survival, indicating that constitutively active Syk contributes to the growth of these malignancies. 26, 27, 30, 31 In addition, translocations involving Syk have recently been identified in patients with myelodysplastic syndrome and peripheral T-cell lymphoma, further suggesting that this kinase may function as a proto-oncogene. These translocations generate fusion proteins in which the tyrosine kinase domain of Syk is joined to the dimerization domain of the transcription factor TEL or to the N-terminal pleckstrin homology domain of the inducible T cell kinase. 32, 33 Functional studies with TEL-Syk have shown that this protein is constitutively active and capable of inducing growth factor-independent proliferation of mouse pre-B cells, further indicating that deregulated Syk activity may contribute to the pathogenesis of common B-cell malignancies. 32, 34 Aberrant expression and activation of the Src-family kinase Lyn, which can activate Syk by phosphorylating Y352, has recently been observed in CLL. 35 This finding, together with the constitutive activation of Syk in other B-cell malignancies, prompted us to investigate the activation status of Syk in a large series of primary CLL samples. In addition, we investigated the effects of a novel pharmacological inhibitor of Syk, R406, on the intracellular signaling and survival of CLL cells. We show that Syk is constitutively active in most CLL B-cell samples and affects the basal activity of important downstream signaling pathways. Moreover, inhibition of Syk with R406 reduces Mcl-1 expression and leukemic cell survival, suggesting that this kinase may represent a promising target for the treatment of CLL.
Materials and methods

Patient samples
Blood samples were collected from patients who satisfied standard morphologic and immunophenotypic criteria for B-cell CLL. Informed consent was obtained from all patients according to the Declaration of Helsinki, and approval for the study was obtained from the institutional human research committee at the Catholic University Hospital 'A Gemelli'. Peripheral blood mononuclear cells were separated by Ficoll gradient centrifugation, and CLL B cells were purified by negative selection with anti-CD3, anti-CD14 and anti-CD16 mouse monoclonal antibodies (kindly provided by Professor Fabio Malavasi, University of Turin, Italy) and Dynabeads coated with anti-mouse IgG (Dynal Biotech, Oslo, Norway). The purity of the selected B-cell populations was evaluated by staining with anti-CD5 R-phycoerythrin-conjugated antibodies and anti-CD19 fluorescein isothiocyanate-conjugated antibodies (BD Biosciences, Franklin Lakes, NJ, USA), followed by flow cytometric analysis on a FACSCalibur flow cytometer (BD Biosciences). In all cases, the purity of the CLL B-cell samples exceeded 98%.
Cell lines and culture conditions
Freshly isolated CLL B cells and the human lymphoma cell lines BJAB, B104, DHL-4, DHL-6, DHL-8, DHL-10, Toledo and WSU were cultured in Roswell Park Memorial Institute (RPMI)-1640 supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine and 1 mM sodium pyruvate (Invitrogen, Carlsbad, CA, USA) at 37 1C in the presence of 5% CO 2 . The interleukin (IL)-3-dependent mouse pro-B cell line BaF3 was maintained under the same conditions except for the presence of 5 ng/ml recombinant mouse IL-3 (R&D Systems, Minneapolis, MN, USA). CLL, B104 and BJAB B cells (1 Â 10 7 /ml) were stimulated at 37 1C for the indicated times with 10 mg/ml goat F(ab') 2 anti-human IgM (Southern Biotechnology Associates, Birmingham, AL, USA) or with 40 ml/ml of Dynabeads coated with anti-human IgM (immobilized anti-IgM), as described elsewhere. 25, 26 In some experiments, CLL cells were treated with PP2 (Calbiochem-Merck, Darmstadt, Germany), fludarabine (Schering, Berlin, Germany), Piceatannol (Sigma-Aldrich, St Louis, MO, USA) and R406 (kindly provided by Rigel Pharmaceuticals Inc., South San Francisco, CA, USA). R406 was dissolved in dimethylsulfoxide (DMSO) at a concentration of 10 mM and stored at À80 1C. Prior to usage, R406 was serially diluted in DMSO and then in complete RPMI medium. The final DMSO concentration in the culture medium was 0.5%; the same concentration of DMSO was used as solvent control. The pancaspase inhibitor Z-VAD-fmk (BD Biosciences) was used at 100 mM.
Production of TEL-Syk expression vector and stable BaF3 transfectants
Cloned human Syk cDNA (pCMVXL5-Syk) was purchased from OriGene Technologies Inc. (Rockville, MD, USA) and subcloned into pcDNA3.1( þ ) (Invitrogen). Subsequently, the FLAG-epitope tag was added to the C-terminus of Syk. The dimerization PNT domain of the transcription factor TEL was next amplified by reverse transcriptase-PCR and subcloned into the XhoI and XbaI sites of the pcDNA3.1( þ )-Syk-FLAG vector to generate TEL-Syk. Plasmid DNA for transfection was purified with the EndoFree Plasmid Maxi Kit (Qiagen, Hilden, Germany). The TEL-Syk plasmid and the control pcDNA3.1( þ ) vector were then linearized with PvuI and transfected by nucleofection into 8 Â 10 6 BaF3 cells using Nucleofector Solution V and the T20 program (Amaxa Biosystems GmbH, Cologne, Germany). Stable transfectant clones were obtained by limiting dilution and selection in Geneticin/G418 (Invitrogen). Expression of TEL-Syk protein was verified by immunoblotting using antibodies against Syk and FLAG.
Immunoblotting analysis
Cell pellets were lysed in ice-cold RIPA lysis buffer (10 Analysis of NF-kB activity by electrophoretic mobility shift assay CLL cells (5 Â 10 6 ) were resuspended in 20 ml of buffer A (10 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 10mM KCl, 1:30 dilution of protease and 1:75 dilution of phosphatase inhibitor cocktail) and incubated on ice for 10 min. Cells were then lysed by incubating on ice for additional 10 min in buffer A containing 0.1% NP40, after which time they were centrifuged at 12 000 g for 10 min. The pellet was resuspended in buffer C (20 mM HEPES, pH 7.9, 420 mM NaCl, 1.5 mM MgCl 2 , 25% glycerol and protease/phosphatase inhibitor cocktail) and incubated on ice for 30 min. The nuclear extract was recovered by collecting the supernatant after centrifugation for 10 min at 15 600 g. The protein from nuclear extracts was quantified with the RC DC Protein Assay (Bio-Rad Laboratories). Equal amounts of nuclear protein (5 mg) were incubated with 32 P-radiolabeled oligonucleotide probes containing a consensus NF-kB binding site. The binding reaction was performed in binding buffer (4% glycerol, 1 mM ethylenediaminetetraacetic acid, 10 mM Tris, pH 7.5, 100 mM NaCl, 0.1 mg/ml nuclease-free bovine serum albumin, 5 mM dithiothreitol) with the addition of 2 mg of poly dIdC (Amersham Biosciences) for 30 min at room temperature. Protein-DNA complexes were then separated by native 5% polyacrylamide gel electrophoresis. Gels were dried and NF-kB DNA binding was quantified using a Storm 860 PhosphorImager with ImageQuant 4 software (Molecular Dynamics, Sunnyvale, CA, USA).
Apoptosis assays
In all, 1 Â 10 6 purified CLL B cells were treated with increasing concentrations of PP2, Piceatannol or R406 in complete RPMI medium for 48 h. Spontaneous and drug-induced apoptosis were evaluated by double staining with propidium iodide and Annexin-A5-fluorescein isothiocyanate conjugate (Nexins Research, Kattendijke, The Netherlands), according to the manufacturer's instructions. Samples were analyzed on a FACSCalibur flow cytometer with the CellQuest software (BD Biosciences). The percentage of R406-induced apoptosis was calculated using the following formula: [(% apoptotic cells in the presence of R406À% apoptotic cells in the presence of solvent control)/% apoptotic cells in the presence of R406] Â 100.
Immunofluorescence and confocal microscopy analysis
In all, 1 Â 10 5 unstimulated or anti-IgM-stimulated CLL and BJAB B cells were resuspended in 50 ml of ice-cold phosphatebuffered saline (PBS) and allowed to adhere to poly-L-Lysinecoated coverslips for 15 min at 4 1C. Cells were fixed for 15 min in 4% paraformaldehyde and 1 mM Na 3 VO 4 in PBS, washed two times with PBS and permeabilized for 5 min at room temperature with 1% Triton-X-100 in PBS. Cells were then incubated in blocking buffer (10% fetal calf serum, 0.1% Tween-20 in PBS) at room temperature for 1 h, stained with phospho-Syk Tyr352 antibody for 2 h, washed and incubated with Alexa-Fluor 555-conjugated goat anti-rabbit IgG antibody for 1 h (Invitrogen). Cells were subsequently washed, stained with Hoechst 33332 and the coverslips were mounted on the slides. Confocal microscopy analysis was performed with the Leica TCS-SP5 system (Leica Microsystems GmbH, Wetzlar, Germany).
Statistical analysis
The difference in the percentage of apoptosis induced by R406 alone or R406 in combination with Fludarabine or PP2 were evaluated with the paired t-test. The relationship between the various prognostic factors (variable heavy chain (V H ) gene mutation status, ZAP-70 expression and cytogenetic abnormalities) and expression of Y352-phosphorylated Syk or sensitivity to R406-induced apoptosis was examined using the Mann-Whitney Rank Sum test. All statistical analyses were performed using the SigmaStat 3.1 program (Systat Software, Richmond, CA, USA).
Results
Syk is constitutively phosphorylated at the activating Y352 residue in CLL B cells
To investigate whether Syk is constitutively active in CLL B cells, as recently reported for other B-cell malignancies, we performed immunoblotting analysis using a phospho-specific antibody that recognizes Syk when phosphorylated on the activating Y352 residue. The lymphoma B-cell line BJAB was used as a negative control in these experiments, because preliminary data showed that Syk is not phosphorylated at Y352 in these cells in the absence of BCR crosslinking. Experiments were performed with cellular extracts from more than 40 freshly isolated CLL B-cell samples. Although no signal could be detected in unstimulated BJAB cells, substantial levels of Y352-phosphorylated Syk were evident in a large fraction of the CLL samples ( Figure 1a and data not shown).
To more precisely determine the amount of Y352-phosphorylated Syk in CLL B cells, we performed a second set of experiments in which we compared the intensity of the phospho-specific signal in 25 CLL samples with the signal in the DLBCL cell lines DHL-4, DHL-6, WSU and DHL-10 ( Figure 1b ). These DLBCL cell lines had been reported earlier to express constitutively phosphorylated and active Syk. 30 To quantify the relative phospho-Syk levels in these samples, we used as an internal standard the lymphoma B-cell line B104, which also expresses constitutively phosphorylated Syk. As shown in Figure 1c , the phospho-Syk signal in the CLL B-cell samples was equivalent to or exceeded the signal in the DLBCL cell lines, suggesting that CLL lymphocytes express substantial amounts of active Syk protein. The amount of Y352-phosphorylated Syk varied between the different CLL samples, but did not correlate with any of the investigated clinical and laboratory features, including V H gene mutation status, ZAP-70 and CD38 expression, and necessity for treatment ( Figure 1d and Table 1 ).
To further validate the results of the immunoblotting experiments and to assess the intracellular distribution of Y352-phosphorylated Syk, we performed confocal microscopy on unstimulated and anti-IgM-stimulated CLL, BJAB and B104 cells ( Figure 2 ). In unstimulated BJAB cells, which were used as a negative control, Y352-phosphorylated Syk was not detected. In these cells, a fluorescent signal appeared only after anti-IgM stimulation, initially as patched and subsequently as capped structures that were distributed across the plasma membrane. In contrast, CLL and B104 cells expressed Y352-phosphorylated Syk even in the absence of BCR engagement. The phospho-Syk signal in unstimulated CLL and B104 cells was located not only at the plasma membrane but also in the cytoplasm and nucleus. Treatment of these cells with anti-IgM increased the intensity of the signal and also induced the formation of patched and capped structures, although these structures appeared less frequently and were less defined than in BJAB cells.
The Syk inhibitors Piceatannol and R406 induce apoptosis in CLL cells
We next investigated whether phosphorylation of Syk at Y352 in CLL cells was a result of aberrant Lyn kinase activity. To this Constitutive activation of Syk in B-CLL S Gobessi et al end, we treated CLL B cells with the Src-family kinase inhibitor PP2. A phospho-specific antibody recognizing the active form of Src-family kinase members (pSrc Y416 /pLyn Y397 ) was used to monitor inhibition of Lyn. As shown in Figure 3a , treatment with PP2 inhibited phosphorylation of Lyn on the activating tyrosine residue and resulted in substantial reduction or disappearance of the phospho-Syk signal.
Inhibition of Lyn with PP2 has been shown to induce apoptosis in CLL B cells. 35 We, therefore, investigated whether inhibition of Syk will also affect leukemic cell viability. In initial experiments, we tested the Syk inhibitor Piceatannol, which induced apoptosis at a rate that was comparable to PP2 over the same dose range (Figure 3b ). These findings encouraged us to test R406, which is a novel Syk inhibitor that has completed phase 1 studies and is currently undergoing phase 2 trials in patients with rheumatoid arthritis and lymphoma. 30, 36 Treatment of CLL cells for 48 h with increasing concentrations of R406 showed a statistically significant increase in the percentage of apoptotic cells (Figure 3c and Supplementary Table 1) . Induction of apoptosis was maximal with 2.5 mM R406, which showed a more than 10% increase in the percentage of Annexin V-positive cells in 31 of the 44 investigated cases (Figure 3d) . Interestingly, higher concentrations of R406 (10 mM) did not further increase the percentage of apoptotic cells (data not shown). Sensitivity to R406 was highly variable, but did not correlate with any of the major biological prognostic factors, including V H gene mutation status, ZAP-70 expression and presence of the high-risk cytogenetic abnormalities del17p13 and del11q22 (Figure 3e and Supplementary Table 2) .
We also investigated in a series of 13 CLL samples whether combining R406 with Fludarabine or PP2 will enhance the cytotoxic effect of each compound alone. As shown in Figure 3f , the addition of R406 significantly increased the cytotoxicity of Fludarabine. In contrast, R406 did not augment the cytotoxic effect of PP2, further suggesting that these two inhibitors induce apoptosis by blocking the same pro-survival pathway.
Inhibition of Syk by R406 reduces the basal activity of the Akt and ERK signaling pathways
To get an insight into the mechanism(s) responsible for R406-induced apoptosis, we first evaluated the effects of this inhibitor Table 1 . CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma.
on the basal activity of the PI3K/Akt, MEK/ERK and NF-kB pathways. These pathways can be activated in CLL B cells by BCR stimulation and have been shown to increase the survival of the leukemic cells in vitro. 25, 26, [37] [38] [39] [40] As shown in Figure 4a , short treatment of CLL B cells with increasing concentrations of R406 resulted in a dose-dependent reduction in basal Akt phosphorylation and induced a more prominent reduction in the phosphorylation of glycogen synthase kinase (GSK)-3 and FoxO1/3a, both of which are direct substrates of Akt. In addition, R406 reduced the phosphorylation of ERK in those cases where the basal phosphorylation of this kinase could be detected. In contrast, the DNA binding activity of NF-kB in nuclear extracts prepared from R406-treated cells was not affected, suggesting that the high basal NF-kB activity typically displayed by CLL B cells is not a consequence of constitutive Syk activation (Figure 4b ). [38] [39] [40] Although R406 is considered a relatively specific Syk inhibitor, it still remained possible that the effects on Akt and ERK signaling are due to the inhibition of another upstream kinase that is common to both pathways. Previous selectivity screens using a large panel of cell-based and biochemical assays had shown that R406 can also inhibit other kinases, including Lyn and other Src-family kinase members, but the concentrations required to inhibit these kinases were found to be substantially higher than those required to inhibit Syk. 36, 41 This was confirmed by the experiments shown in Figure 4c , in which only the highest concentration of R406 (2.5 mM) induced a minor reduction in Lyn kinase activity, as assessed by the analysis of Lyn autophosphorylation at Y397 and Syk phosphorylation at Y352. By contrast, the inhibition of direct targets of Syk, such as Y700 and Y774 in Cbl and Y84 in BLNK, was already evident with the 0.16 mM R406 concentration. It is noted that the concentrations that inhibited the phosphorylation of Cbl and BLNK were also effective in reducing the basal phosphorylation of Akt, GSK-3, FoxO1/3a and ERK (Figure 4a ). To further ascertain whether the effects on Akt and ERK signaling were due to the inhibition of Syk rather than Lyn, we investigated the capacity of R406 to inhibit the activation of Akt and ERK in cells expressing the constitutively active TEL-Syk fusion protein. Earlier studies have shown that TEL-Syk, which contains the kinase domain of Syk linked to the dimerization domain of TEL, can induce growth factor-independent activation of Akt and ERK when expressed in the IL-3-dependent B-cell line BaF3. 42 We, therefore, transfected a TEL-Syk expression vector and a control pCDNA3 plasmid into BaF3 cells and generated stable clones by G418 selection. In the absence of IL-3, phosphorylation of Akt and ERK was observed in TEL-Sykexpressing cells, but not in cells transfected with the control vector (Figure 4d ). Treatment of TEL-Syk-expressing cells for 1 h with R406 inhibited phosphorylation of Akt and ERK at the same Cases marked with + have not received treatment; in these cases the number refers to time from diagnosis to last examination. c The relative phospho-Syk level was determined as described in Figure 1 .
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concentrations that were effective in inhibiting these kinases in CLL B cells, thus confirming that the effects of R406 on downstream signaling are a consequence of Syk inhibition.
R406 inhibits Mcl-1 expression in CLL cells
We recently showed that sustained activation of the Akt kinase increases apoptosis resistance in CLL B cells by increasing the expression of the anti-apoptotic protein Mcl-1. 25, 26 As R406 inhibited the basal activity of the Akt signaling pathway, we decided to investigate whether this treatment would also affect basal Mcl-1 expression. Incubation of purified CLL cells for 48 h with increasing concentrations of R406 (0.04-2.5 mM) resulted in a dose-dependent reduction in Mcl-1 levels in seven out of eight investigated cases (Figure 5a and data not shown). Downregulation of Mcl-1 appeared rather specific, as the same concentrations of R406 did not affect the levels of the antiapoptotic proteins Bcl-2 and Bcl-xL and induced only a modest decrease in the levels of XIAP. The decrease in Mcl-1 was associated with induction of apoptosis, as evidenced by cleavage of the caspase 3 substrate poly(ADP-ribose)polymerase (PARP) and an increase in the percentage of Annexin V-positive cells.
Mcl-1 is a short-lived protein (half-life 1-2 h), the expression of which can additionally decline in dying cells because of caspase-mediated cleavage. 43 Therefore, to verify whether downregulation of Mcl-1 is a cause rather than a consequence of R406-induced apoptosis, we performed time course experiments in which we evaluated the temporal relationship between Mcl-1 inhibition and caspase activation. CLL cells were treated with R406 or solvent control, and cellular extracts were prepared after 2, 5, 18 and 27 h of treatment. The difference in the levels of Mcl-1 between cells treated with R406 and cells treated with solvent control became evident already after 5 h, whereas the difference in the amount of cleaved PARP protein was observed after 18-27 h (Figure 5b) .
To further confirm that R406 directly inhibits Mcl-1 expression, we performed experiments with the pan-caspase inhibitor Z-VAD-fmk (Figure 5c ). CLL cells were treated with R406 or solvent control in the presence or absence of Z-VAD-fmk, and were evaluated for Mcl-1 expression and PARP cleavage after 28 h. In the presence of Z-VAD-fmk, both spontaneous and R406-induced leukemic cell apoptosis were almost completely inhibited, as evidenced by a significant reduction in the amount of cleaved PARP protein. Despite this inhibition of caspase activity, a significant reduction in Mcl-1 levels was observed in cells treated with R406. Taken together, these data show that R406-induced downregulation of Mcl-1 is primarily a consequence of direct inhibition of signaling pathways that regulate Mcl-1 expression.
R406 blocks the survival signal induced by sustained BCR engagement
The previous experiments showed that R406 inhibits expression of Mcl-1 and induces apoptosis in unstimulated CLL B cells. However, Mcl-1 expression and apoptosis resistance can be increased by many signals from the leukemic cell microenvironment, including antigen stimulation of the BCR. As the Syk kinase propagates the antigenic stimulus downstream of the BCR, we investigated whether R406 can prevent the increase in Mcl-1 expression and the increased apoptosis resistance induced by sustained BCR engagement. As shown in Figure 6 
Discussion
In the present study, we report that the Syk kinase is constitutively phosphorylated on the activating tyrosine 352 residue in leukemic cells of most patients with CLL. Phosphorylated Syk was detected by immunoblotting and/or immunofluorescence analysis using the BJAB B-cell line as a negative control and confirmed in experiments with the Src kinase inhibitor PP2. In the latter experiments, a significant reduction or complete disappearance of the phospho-specific signal was observed, indicating that Syk is continuously phosphorylated at Y352 by Lyn or related Src-family kinases. Given that constitutive phosphorylation of Syk has also been observed in DLBCL, follicular lymphoma and mantle cell lymphoma, these findings indicate that deregulated activation of Syk may contribute to the pathogenesis of many common B-cell malignancies. We also show that Y352-phosphorylated Syk is enzymatically active, as evidenced by experiments with the Syk inhibitor R406, which showed inhibition in the basal phosphorylation of the direct Syk targets BLNK and Cbl. 44, 45 In addition, the Constitutive activation of Syk in B-CLL S Gobessi et al treatment of CLL cells with R406 decreased the basal activity of several downstream signaling molecules that play important roles in regulating CLL-cell survival, such as the Akt, ERK and GSK-3 kinases and the FoxO1/3a transcription factors. 25, 26, 37, 46, 47 The specificity of R406 in inhibiting Syk-mediated activation of Akt and ERK was further confirmed in experiments with a constitutively active TEL-Syk protein. Interestingly, R406 treatment had no effect on the DNA-binding activity of the NF-kB transcription factor, which is another potential Syk target that shows high basal activity in CLL B cells. [38] [39] [40] Our data are consistent with studies performed with DLBCL cell lines, which showed that the inhibition of Syk with the inhibitor curcumin or the downregulation of Syk by RNA interference reduces basal Akt phosphorylation. 31 It should be noted, however, that in unstimulated CLL cells the levels of phosphorylated Akt and ERK are relatively low, especially in comparison with CLL cells stimulated through the BCR. . Nuclear extracts were prepared from each sample and were assayed for NF-kB DNA binding activity by EMSA. The specificity of the NF-kB binding was confirmed by an EMSA cold competitor assay, using a nonradioactive NF-kB oligonucleotide probe that was added at a 10 Â greater concentration than the radioactively labeled probe (lanes labeled with competitor þ ). NF-kB binding to the radioactively labeled probe was inhibited by the nonlabeled probe in all three samples, but was not affected by R406. ) was used to assess the basal level of Akt and ERK phosphorylation. Cells were first deprived from interleukin-3 for 12 h to eliminate the cytokine-induced phosphorylation of Akt and ERK and then incubated for 1 h with the indicated concentrations of R406. TEL-Syk was distinguished from endogenous (endo.) Syk by the difference in molecular weight. ERK was used as a loading control. EMSA, electrophoretic mobility shift assay; ERK, extracellular signal-regulated kinase, CLL, chronic lymphocytic leukemia.
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Nevertheless, despite this low basal phosphorylation, we observed considerable Akt activity, as evidenced by substantial phosphorylation of GSK-3 and FoxO1/3a at sites that are known to be direct targets of this kinase.
Treatment of CLL lymphocytes with the Syk inhibitors Piceatannol and R406 induced leukemic cell apoptosis in the majority of the investigated samples. It is noted that the cytotoxic effect of R406 was observed at concentrations shown earlier to induce apoptosis in human DLBCL cell lines and to inhibit the proliferation of mouse B cells transformed with the TEL-Syk protein. 30, 34 Sensitivity to R406 treatment varied between different CLL samples, but did not correlate with any of the major biological prognostic factors, including V H gene mutation status, ZAP-70 expression or presence of high-risk cytogenetic abnormalities. In addition, the cytotoxic effect of R406 was not always proportional to the amount of Y352-phosphorylated Syk (data not shown). In the case of DLBCL, Chen et al. 30 also observed that some of the cell lines that expressed Y352-phosphorylated Syk were not sensitive to R406 treatment, indicating that other factors may also play a role in determining sensitivity to R406-induced apoptosis. In that study, a better correlation was observed when sensitivity to R406 was compared with the capacity of the DLBCL cells to phosphorylate YY525/526 of Syk and Y84 of BLNK following BCR crosslinking. Considering that CLL cells also differ in their capacity to transmit signals through the BCR, it will be worth investigating in future studies whether resistance to R406-induced apoptosis, which was observed in a minority of cases, is due to defective propagation of the signal downstream of Syk. Hopefully, such studies may identify predictors of R406 sensitivity that will be useful in the clinical setting.
Induction of apoptosis by R406 was associated with downregulation of the anti-apoptotic protein Mcl-1, which is posttranscriptionally regulated in CLL B cells by the Akt kinase. 26 The decrease in Mcl-1 expression preceded and was independent of caspase activation, suggesting that Mcl-1 downregulation is a cause rather than a consequence of apoptosis. Recent studies have shown that CLL B cells are markedly dependent on Mcl-1 expression, as evidenced by a substantial decrease in leukemic cell viability following specific downregulation of this protein by RNA interference or by treatment with small molecule antagonists. 26, 48, 49 Moreover, higher levels of Mcl-1 have been observed in freshly isolated CLL B cells from patients with poor prognostic features and a more aggressive clinical course. 50 In addition, elevated Mcl-1 expression was found to correlate strongly with in vitro resistance to fludarabine, 25 Stimulation of CLL B cells with immobilized anti-IgM also increases the resistance to spontaneous and chemotherapy-induced apoptosis. We now show that R406 can completely block the anti-IgM-induced Akt activation, Mcl-1 upregulation and consequent increase in leukemic cell survival, suggesting that Syk may be an optimal target for therapeutic strategies aimed at disrupting the anti-apoptotic BCR signal.
The orally bioavailable prodrug of R406 has already been tested in animal studies and in human clinical trials, which showed lack of significant toxicities or adverse effects at doses that effectively inhibit the kinase activity of Syk. 36, 57 These promising results have resulted in ongoing phase 2 clinical trials in patients with rheumatoid arthritis and B-cell lymphoma. Given the lack of significant safety issues, the in vitro efficacy against primary unstimulated CLL cells and the potential to inhibit BCR signaling in vivo, it appears reasonable to conclude that this compound requires further evaluation in clinical trials of CLL. The mechanism(s) responsible for the constitutive activation of Syk in CLL and other B-cell malignancies are unclear at present. Time course experiments in which CLL B cells were cultured for extended periods (up to 48 h) in complete or serumfree medium did not result in diminished Y352 phosphorylation (data not shown), indicating that the activation of Syk was not caused by antigen stimulation. For the same reason, antigendependent Syk activation can also be excluded in the case of DLBCL and other types of lymphomas. An alternative explanation for constitutive Syk activation is that it is a consequence of exaggerated tonic BCR signaling. 18 Tonic or ligand-independent BCR signals are considered necessary for the maintenance and survival of both normal and malignant B cells (reviewed in 18 and 58 ). These signals are generated by transient and stochastic interactions of the BCR complex with positive regulatory molecules and are quickly terminated by negative regulators of signaling. The latter include protein-tyrosine phosphatases that dephosphorylate Syk and other molecules involved in proximal BCR signaling, as well as ubiquitin ligases that target activated Syk for proteasomal degradation. Thus, the constitutive activation of Syk could result from the inadequate expression or function of a negative regulator of BCR signaling. Supporting this possibility is the recent observation that the phosphatase, protein tyrosine phosphatase receptor-type O truncated (PTPROt), which directly dephosphorylates Syk is downregulated in CLL relative to normal lymphocytes as a consequence of promoter methylation and silencing. 59, 60 In summary, this study shows that CLL B cells frequently express constitutively active Syk, which contributes to leukemic cell survival by increasing the basal activity of the Akt/Mcl-1 pathway. The activity of this pathway can be downregulated by specific Syk inhibitors, such as R406, which can also prevent transmission of anti-apoptotic signals originating from the antigen-stimulated BCR. Thus, the pharmacological inhibition Figure 6 R406 inhibits the anti-apoptotic signal induced by sustained BCR engagement. CLL cells were preincubated for 1 h with 2.5 mM R406 before the addition of immobilized anti-IgM antibody (imm-IgM) and collected 24 h later. Phosphorylation of Syk, Akt and GSK-3, and expression of Mcl-1 were investigated by western blotting. Bcl-2 served as a loading control. Protection from apoptosis was evaluated by PARP cleavage and Annexin V/propidium iodide staining. Four independent experiments are shown. int., intact; cl., cleaved. PARP, poly(ADP-ribose)polymerase; GSK, glycogen synthase kinase; BCR, B-cell receptor; CLL, chronic lymphocytic leukemia.
of Syk could provide a double therapeutic benefit, by disrupting both antigen-dependent and antigen-independent signaling pathways that contribute to the growth and survival of the malignant clone.
